Literature DB >> 30362418

CDK9 as an Appealing Target for Therapeutic Interventions.

Shirin Eyvazi1,2, Mohammad Saeid Hejazi1,3,4, Homan Kahroba1,4, Mozghan Abasi1,2, Reza Eghdam Zamiri5, Vahideh Tarhriz1.   

Abstract

Cyclin Dependent Kinase 9 (CDK9) as a serine/threonine kinase belongs to a great number of CDKs. CDK9 is the main core of PTEF-b complex and phosphorylates RNA polymerase (RNAP) II besides other transcription factors which regulate gene transcription elongation in numerous physiological processes. Multi-functional nature of CDK9 in diverse cellular pathways proposes that it is as an appealing target. In this review, we summarized the recent findings on the molecular interaction of CDK9 with critical participant molecules to modulate their activity in various diseases. Furthermore, the presented review provides a rationale supporting the use of CDK9 as a therapeutic target in clinical developments for crucial diseases; particularly cancers will be reviewed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  CDK9; RNAP; cancer; cardiac pathway; fibrosis; inflammation; viral agents.

Mesh:

Substances:

Year:  2019        PMID: 30362418     DOI: 10.2174/1389450119666181026152221

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  6 in total

Review 1.  Exosomes: from carcinogenesis and metastasis to diagnosis and treatment of gastric cancer.

Authors:  Houman Kahroba; Mohammad Saeid Hejazi; Nasser Samadi
Journal:  Cell Mol Life Sci       Date:  2019-02-08       Impact factor: 9.261

2.  Selective Cdk9 inhibition resolves neutrophilic inflammation and enhances cardiac regeneration in larval zebrafish.

Authors:  Aryan Kaveh; Finnius A Bruton; Magdalena E M Oremek; Carl S Tucker; Jonathan M Taylor; John J Mullins; Adriano G Rossi; Martin A Denvir
Journal:  Development       Date:  2021-10-26       Impact factor: 6.862

3.  A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets.

Authors:  Xiang Li; Chun-Hao Huang; Francisco J Sánchez-Rivera; Margaret C Kennedy; Darjus F Tschaharganeh; John P Morris; Antonella Montinaro; Kevin P O'Rourke; Ana Banito; John E Wilkinson; Chi-Chao Chen; Yu-Jui Ho; Lukas E Dow; Sha Tian; Wei Luan; Elisa de Stanchina; Tinghu Zhang; Nathanael S Gray; Henning Walczak; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-20       Impact factor: 12.779

Review 4.  Exosome-based strategies for diagnosis and therapy of glioma cancer.

Authors:  Mohsen Karami Fath; Jalil Azami; Alireza Masoudi; Reza Mosaddeghi Heris; Elnaz Rahmani; Fatemeh Alavi; Armina Alagheband Bahrami; Zahra Payandeh; Bahman Khalesi; Masoomeh Dadkhah; Navid Pourzardosht; Vahideh Tarhriz
Journal:  Cancer Cell Int       Date:  2022-08-21       Impact factor: 6.429

5.  Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.

Authors:  Shen Shen; Dylan C Dean; Zujiang Yu; Francis Hornicek; Quancheng Kan; Zhenfeng Duan
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

Review 6.  Potential Roles of MyomiRs in Cardiac Development and Related Diseases.

Authors:  Leila Abkhooie; Mostafa M Sarabi; Houman Kahroba; Shirin Eyvazi; Soheila Montazersaheb; Vahideh Tarhriz; Mohammad S Hejazi
Journal:  Curr Cardiol Rev       Date:  2021
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.